Animal study · mice

Survodutide: more weight loss than semaglutide in mice

Checked against the paper Animal studyPublished by PepVault

The takeaway

This early lab paper shows that survodutide acts on both the glucagon and GLP-1 receptors and beat semaglutide for weight loss in mice; whether that holds in people is a question for human trials.

Kind
Animal study
Studied in
Mice
Published
2022
Journal
Mol Metab

What they tested

The team set out to describe how survodutide (BI 456906) acts at two receptors, the glucagon receptor and the GLP-1 receptor, and whether it lowers body weight.

How the study was done

A preclinical study that used lab cell tests and mice given acute or repeated short-term (subchronic) doses, compared against semaglutide. It also used mice lacking the GLP-1 receptor (knockout mice), transgenic reporter mice, and an ex vivo bioactivity assay.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking survodutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In mice, pharmacological doses of survodutide cut body weight more than maximally effective doses of semaglutide, a GLP-1 receptor drug. The extra effect came from more energy burned plus less food eaten. Action at the GLP-1 receptor showed up in glucose tolerance, food intake and gastric emptying (how fast the stomach empties) tests. Action at the glucagon receptor showed up in liver nicotinamide N-methyltransferase mRNA levels and blood markers, including amino acids and fibroblast growth factor-21.

What it doesn’t show

This is mouse and cell work, so it is not a result in people. The mouse dosing was short-term, and the study did not test survodutide in humans.

The paper

Zimmermann et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022.

The compound

More studies on Survodutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking survodutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo